Summary & Overview
CPT 0709T: Follow-up Intradermal Cancer Immunotherapy Injection
CPT code 0709T denotes a subsequent intradermal cancer immunotherapy injection administered by a provider after an initial dose. This procedure code captures a specific follow-up therapeutic injection used in emerging cancer immunotherapy protocols, reflecting the growing role of intradermal immunotherapies in oncology care. Nationally, precise coding for follow-up injections matters for care continuity, clinical documentation, and accurate payment for evolving immunotherapy services.
Key payers referenced for coverage context include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose, where the service is typically delivered, common modifiers used with this service, and the payer landscape addressed. The publication outlines benchmarks and coverage considerations relevant to this procedure, summarizes coding relationships, and provides clinical context for billing teams and oncology providers.
The content is intended to help revenue cycle, coding, and clinical staff understand the role of CPT code 0709T in documenting follow-up intradermal cancer immunotherapy injections, improve claim accuracy, and align clinical notes with billing requirements. Data not available in the input is noted where applicable.
Billing Code Overview
CPT code 0709T describes a follow-on intradermal cancer immunotherapy injection administered by a provider after an initial injection. The service is a therapeutic intradermal injection used as part of a cancer immunotherapy regimen.
-
Service type: Intradermal cancer immunotherapy injection (follow-up dose)
-
Typical site of service: Outpatient clinic or ambulatory infusion/oncology clinic
Clinical & Coding Specifications
Clinical Context
A patient with a superficial cutaneous malignancy (for example, cutaneous melanoma in situ or recurrent cutaneous squamous cell carcinoma) presents to a dermatology clinic for repeat intradermal immunotherapy following an initial injection. The patient is typically an adult who previously tolerated the first session without systemic adverse events and is scheduled for a follow-up session to administer an additional intradermal cancer immunotherapy dose at the same treatment site or adjacent lesions. The clinical workflow includes a brief pre-procedure assessment (vital signs, review of prior reaction), verification of informed consent and immunotherapy lot/expiration, site cleaning, local intradermal injection by the provider, observation for immediate local or systemic reaction for 15–30 minutes, and documentation of dose, lot number, injection site, and patient tolerance. The procedure is frequently performed in an outpatient dermatology clinic, ambulatory surgery center, or oncology clinic equipped for minor office procedures and emergency response. Typical personnel include a dermatologic or surgical oncologist (or trained procedural dermatologist), a registered nurse for preparation and monitoring, and ancillary administrative staff for scheduling and billing. Post-procedure instructions and follow-up are documented, and additional injections are scheduled per the treatment protocol.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when the intradermal injection requires substantially greater effort, time, or skill than usual due to complexity or unusual circumstances. |